Tagged with diagnostics,

Hong Kong Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong sheds light on the Asian diagnostics market and unveils his strategy to expand Xcelom’s offering across Asia.   Our pursuit…

Hong Kong Kelvin Chiu and Isabelle Dutry of Sanwa BioTech in Hong Kong highlight the critical importance of personalised fast-track diagnostics in countering the COVID-19 pandemic, the role that Asian firms have to play in remedying the global shortage of medical supplies, and what the future holds for Sanwa.   Looking at…

Taiwan Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have to play in more effective COVID-19 diagnostics.   Given our status as a raw materials developer, we see an opportunity…

Coronavirus During a global virtual press briefing on 19 March 2020, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) gathered five global pharmaceutical leaders including Roche Chairman and CEO Severin Schwan to discuss the global ramifications of the COVID-19 crisis.   With Roche’s global leadership in diagnostics, many of the questions…

Morocco Yassine Houbachi discusses his strategy for leading Moroccan generics player Polymedic, the market environment in Morocco, and what future challenges may be. In addition, Houbachi introduces RIM Pharma, an innovative young company which is expanding access to oncology diagnostics in Morocco.   The market being stagnant, prices are dropping and…

Coronavirus Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself as the frontrunner in personalized healthcare. In 2012, CEO Severin Schwan set the ambitious target of pairing more than 60…

Taiwan Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for pharma multinationals implanted in Taiwan give their first impressions of the market and what recommends it.    NHI: Bringing the…

Hungary Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving factors behind the company’s success and his long-term vision of for the company.   We grew more than 60 percent…

China Tao Chen, head of business development of Absea and CEO of the new spin-out Agsea, is entering the world of immunodiagnostics with a comprehensive panel of IHC antibodies in the hope of becoming a world leader in pathological diagnostics in just a few years.   Our work at Absea over…

Taiwan The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Kit Tang, general manager of Roche Diagnostics Taiwan, discusses how the Taiwanese affiliate fits…

Taiwan Medimaging Integrated Solution Inc (MiiS) originated from the incubation center at the National Chiao Tung University (NCTU), Taiwan. MiiS started its business primarily based on the foundation of innovation, and their main product is the Horus Scope used for diagnostic imaging. The Founder & CEO, Dr. Stefan Cheng holds a…

Taiwan Tony Chung, CEO of Instant NanoBiosensors explains the potential of their fibre-optic biosensor technology – FOPPR, and the commercialization strategy for their light-sensing biomarker analyzer INB-D200. He also highlights Taiwan’s strengths in developing value-added biomedical technology.   With the trend of precision medicine growing, innovative devices are needed to help…